Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007Ghayas C. Issa, Eunice S. Wang, Amer M. Zeidan et al.|Blood|2025Cited by 7